Clinical Trial Update: Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab in combination with 177Lu-girentuximab for renal cell carcinoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• 177Lu-girentuximab (girentuximab labeled with Lutetium-177)
• nivolumab (nivolumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Clear Cell Renal Cell Carcinoma, Kidney Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING